Research programme: anticancer antibodies - Notable Labs
Alternative Names: VB 600 seriesLatest Information Update: 07 Jun 2024
At a glance
- Originator VBL Therapeutics
- Developer Notable Labs
- Class Antibodies; Antineoplastics
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer